LLL

LIPIGON PHARMACEUTICALS AB

No trades
See on Supercharts
Market capitalization
‪42.86 M‬SEK
−0.3815SEK
‪−12.13 M‬SEK
‪16.41 M‬SEK
Beta (1Y)
−0.29

About LIPIGON PHARMACEUTICALS AB

CEO
Stefan Kristoffer Nilsson
Headquarters
Umeå
Website
Founded
2010
ISIN
SE0015382072
FIGI
BBG00Z6DTDL4
Lipigon Pharmaceuticals AB engages in the development of drugs for diseases caused by disruptions in the body's handling of lipids. It focuses on small molecules, gene therapy, and antisense for patients with lipid disorders and other cardiometabolic risk factors. The company was founded by Stefan Kristoffer Nilsson on April 6, 2010 and is headquartered in Umeå, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of LPGO is 0.3700 SEK — it has increased by 12.12% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange LIPIGON PHARMACEUTICALS AB stocks are traded under the ticker LPGO.
LPGO stock is 21.40% volatile and has beta coefficient of −0.29. Check out the list of the most volatile stocks — is LIPIGON PHARMACEUTICALS AB there?
Yes, you can track LIPIGON PHARMACEUTICALS AB financials in yearly and quarterly reports right on TradingView.
LPGO stock has risen by 25.21% compared to the previous week, the month change is a 4.64% fall, over the last year LIPIGON PHARMACEUTICALS AB has showed a 30.19% decrease.
LPGO net income for the last quarter is ‪−7.56 M‬ SEK, while the quarter before that showed ‪−4.87 M‬ SEK of net income which accounts for −55.22% change. Track more LIPIGON PHARMACEUTICALS AB financial stats to get the full picture.
Today LIPIGON PHARMACEUTICALS AB has the market capitalization of ‪41.72 M‬, it has decreased by 7.03% over the last week.
No, LPGO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LPGO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LIPIGON PHARMACEUTICALS AB stock right from TradingView charts — choose your broker and connect to your account.
LPGO reached its all-time high on Mar 1, 2021 with the price of 10.6665 SEK, and its all-time low was 0.2600 SEK and was reached on Apr 19, 2024.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LIPIGON PHARMACEUTICALS AB technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LIPIGON PHARMACEUTICALS AB stock shows the sell signal. See more of LIPIGON PHARMACEUTICALS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LIPIGON PHARMACEUTICALS AB EBITDA is ‪−12.55 M‬ SEK, and current EBITDA margin is −76.51%. See more stats in LIPIGON PHARMACEUTICALS AB financial statements.